➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Harvard Business School
AstraZeneca
Moodys
McKinsey

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COPANLISIB DIHYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Copanlisib Dihydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01392521 Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer Completed Bayer Phase 1 2011-07-01 The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766)have both been tested as single agent treatments in other phase I studies. This study will test the combination of these two drugs to try and answer the following questions: 1. What are the side effects of the combination of Copanlisib and Refametinib (BAY86-9766)when given together at different/increasing dose levels? 2. What dose level of Copanlisib and Refametinib (BAY86-9766) should be tested in future clinical research studies? 3. How much Copanlisib is in the blood at specific times after administration and does adding Refametinib (BAY86-9766) have an affect? 4. How much Refametinib (BAY86-9766) is in the blood at specific times after administration and does adding Copanlisib have an affect? 5. Does the combination of Refametinib (BAY86-9766) and Copanlisib have an effect on tumors?
NCT01460537 Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer Completed Bayer Phase 1 2011-11-01 This open label Phase I study involves treating subjects with advanced cancer with Copanlisib in combination with either gemcitabine or cisplatin plus gemcitabine. It will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Copanlisib in combination with gemcitabine and Copanlisib in combination with cisplatin and gemcitabine. The trial will involve multiple participating sites from the US. Up to a maximum of 70 subjects will be enrolled in the study.
NCT02119221 Copanlisib Mass Balance Study Completed Bayer Phase 1 2014-02-01 The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.
NCT02155582 Copanlisib Pharmacodynamic Study Active, not recruiting Bayer Phase 1 2014-08-01 This study aims to analyze what the study drug does to the body and its relationship to drug levels and safety after patients with advanced cancer have been treated with copanlisib in different dose groups.
NCT02253420 Copanlisib (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor Patients Recruiting Bayer Phase 1 2014-10-01 In summary, copanlisib is metabolized mainly by the CYP3A4 enzyme, thus a study to evaluate potential DDI (drug-drug interaction) of copanlisib with concomitant CYP3A4 modulators such as Itraconazole (CYP3A4 inhibitor) and Rifampin (CYP3A4 inducer) is necessary. With this regard this study aims to evaluate the effect of Itraconazole or Rifampin on the absorbtion, distribution, metabolization and elimination of Copanlisib (BAY80-6946) . In addition, as parameters of cardiovascular safety , the effect of copanlisib on the heart's ability to pump blood and to rule out copanlisib's potential for causing a specific type of life-threatening arrhythmia, QT/QTc intervals and left ventricular ejection fraction will be evaluated.
NCT02342665 Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL Recruiting Bayer Phase 1/Phase 2 2015-04-01 The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose escalation/safety evaluation part
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Copanlisib Dihydrochloride

Condition Name

Condition Name for Copanlisib Dihydrochloride
Intervention Trials
Metastatic Breast Carcinoma 4
Anatomic Stage IV Breast Cancer AJCC v8 4
Follicular Lymphoma 3
Diffuse Large B Cell Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Copanlisib Dihydrochloride
Intervention Trials
Lymphoma 24
Lymphoma, B-Cell 9
Lymphoma, Non-Hodgkin 8
Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Copanlisib Dihydrochloride

Trials by Country

Trials by Country for Copanlisib Dihydrochloride
Location Trials
United States 79
China 21
Italy 21
Germany 18
Australia 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Copanlisib Dihydrochloride
Location Trials
New York 10
New Jersey 6
Maryland 5
California 5
Washington 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Copanlisib Dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for Copanlisib Dihydrochloride
Clinical Trial Phase Trials
Phase 3 3
Phase 2 12
Phase 1/Phase 2 16
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Copanlisib Dihydrochloride
Clinical Trial Phase Trials
Not yet recruiting 25
Recruiting 21
Completed 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Copanlisib Dihydrochloride

Sponsor Name

Sponsor Name for Copanlisib Dihydrochloride
Sponsor Trials
Bayer 31
National Cancer Institute (NCI) 15
Memorial Sloan Kettering Cancer Center 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Copanlisib Dihydrochloride
Sponsor Trials
Industry 34
Other 30
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
McKesson
Dow
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.